CoChat

Healthcare resource consumption and related costs of patients estimated with treatment‐resistant depression in Italy

Open access
Perrone, Valentina, Sangiorgi, Diego, Andretta, Margherita, Ducci, Giuseppe, Forti, Bruno, Francesa Morel, Pier Cesare, Gambera, Marco, Maina, Giuseppe, Mencacci, Claudio, Mennini, Francesco Saverio, Zanalda, Enrico, Degli Esposti, Luca · 2021 · ClinicoEconomics and Outcomes Research

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

PURPOSE: To analyse the healthcare resource consumption and related costs for the Italian National Health System of patients estimated to be affected by treatment-resistant depression (TRD) in Italy. PATIENTS AND METHODS: This was an observational retrospective study based on administrative databases, including those related to residential/semiresidential structures, of Veneto Region and the Local Health Unit of Bergamo in Italy (for a total of around 6 million health-assisted subjects). Between July 2011 and December 2017, all adult patients with a third antidepressant (AD) after ≥2 AD (each one with at least ≥4 weeks duration, ≥1 prescription at maximum dosage reported in datasheets, a grace period ≤30 days when switching AD and treatment maintained ≥9 months) were included. Overall and psychiatry-related healthcare resources consumption and related costs were estimated on a 12-months based analysis. Data were re-proportioned to the Italian population. RESULTS: We have previously estimated a total of 101,455 patients with TRD in Italy (130,049 considering the mean maximum dosage of AD). Of them, 44.2% had at least a psychiatric hospitalization/visit or accessed a residential/semiresidential structure, and 31% added another AD or a mood stabilizer/antipsychotic drug. Patients with at least one psychiatry-related hospitalization increased over the number of antidepressant lines from 12.0% during first line up to 24.5% during fourth line. Direct healthcare costs increased from €4,405 for first line to €9,251 from fifth line onwards. Psychiatry-related costs went from €1,817 (first line) to €4,606 (fifth line onwards) and were mainly driven by residential/semiresidential structures and hospitalizations. CONCLUSION: An upward trend with number of AD lines was observed for all healthcare resource utilization and consequently for all direct costs, thus indicating an increasing burden for patients as they move forward AD lines.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2147/ceor.s314111

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Criteria applied for the identification of TRD patients.
Figure 1 Criteria applied for the identification of TRD patients.CC BY-NC · PubMed Central
Figure 2 Italian projection of patient distribution according to psychiatric-related resource utilization considering (A) maximum dosage labelled in SMPC and (B) the ratio between mean dosage prescribed/maximum dosage labeled in SMPC.
Figure 2 Italian projection of patient distribution according to psychiatric-related resource utilization considering (A) maximum dosage labelled in SMPC and (B) the ratio between mean dosage prescribed/maximum dosage labeled in SMPC.CC BY-NC · PubMed Central
Figure 3 Psychiatry-related hospitalizations according to antidepressant lines.
Figure 3 Psychiatry-related hospitalizations according to antidepressant lines.CC BY-NC · PubMed Central
Figure 4 Mean annual all-cause and psychiatry-related costs according to antidepressant lines.
Figure 4 Mean annual all-cause and psychiatry-related costs according to antidepressant lines.CC BY-NC · PubMed Central
Figure 5 Mean annual costs of residential/semiresidential structures according to antidepressant lines.
Figure 5 Mean annual costs of residential/semiresidential structures according to antidepressant lines.CC BY-NC · PubMed Central
Figure 6 Mean annual costs of psychiatry-related hospitalizations according to antidepressant lines.
Figure 6 Mean annual costs of psychiatry-related hospitalizations according to antidepressant lines.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 10

Metadata

Authors
Perrone, V., Sangiorgi, D., Andretta, M., Ducci, G., Forti, B., Francesa Morel, P. C., Gambera, M., Maina, G., Mencacci, C., Mennini, F. S., Zanalda, E., & Degli Esposti, L.
Affiliations
  • Azienda ULSS 8 Berica (IT)
  • ASL Roma (IT)
  • Azienda ULSS n. 1 Dolomiti (IT)
  • Ospedale P. Pederzoli – Casa di Cura Privata S.p.a. (IT)
  • University of Turin (IT)
  • ASST Fatebenefratelli Sacco (IT)
  • University of Rome Tor Vergata (IT)
  • Ospedale San Luigi Gonzaga (IT)
Corresponding author
Perrone, Valentina
Venue
ClinicoEconomics and Outcomes Research
Published
2021-07
Volume
Volume 13
Pages
629-635
ISSN
1178-6981 (ISSN-L)
OpenAlex
W3178067180
Cited by
10
References
13
Citations by year
2024: 4 · 2023: 6
FWCI
1.46
Type
journal article
Language
en
Open access
Locations
  • ClinicoEconomics and Outcomes Research (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Research Repository (Kingston University London) (acceptedVersion, cc-by-nc-sa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc-sa)
  • Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
Keywords
treatment-resistant depression, healthcare resource utilization, health care costs, psychiatric hospitalization, mood stabilizers, antipsychotic drugs, Italian National Health Service, Veneto, Bergamo

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.